United Therapeutics (UTHR) Retained Earnings (2009 - 2026)
United Therapeutics (UTHR) reported Retained Earnings of $8.8 billion for Q1 2026, up 17.06% on a YoY basis from $7.5 billion in Q1 2025, and up 981211.11% sequentially from $900000.0 in Q4 2025.
United Therapeutics (UTHR) Retained Earnings (2009 - 2026) Analysis & Trends
United Therapeutics (UTHR) has 18 years of Retained Earnings data on file, last reported at $8.8 billion in Q1 2026.
- For the quarter ending Q1 2026, Retained Earnings rose 17.06% year-over-year to $8.8 billion; the trailing twelve-month figure through Mar 2026 stood at $8.8 billion (up 17.06% YoY), and the FY2025 full-year result was $900000.0, down 99.99% from the prior year.
- Retained Earnings grew to $8.8 billion in Q1 2026, from $900000.0 in the prior quarter.
- In the past five years, Retained Earnings ranged from a high of $8.8 billion in Q1 2026 to a low of -$84.1 million in Q3 2022.
- A 5-year average of $4.5 billion and a median of $5.5 billion in 2023 frame the typical range for Retained Earnings.
- Across the five-year window, Retained Earnings slumped 318.41% in 2022 and jumped 56523.44% in 2024, its largest moves.
- Tracing UTHR's Retained Earnings over 5 years: stood at $5.0 billion in 2022, then plunged by 100.25% to -$12.8 million in 2023, then jumped by 56523.44% to $7.2 billion in 2024, then tumbled by 99.99% to $900000.0 in 2025, then surged by 981211.11% to $8.8 billion in 2026.
- Business Quant data shows UTHR's Retained Earnings at $8.8 billion in Q1 2026, $900000.0 in Q4 2025, and $100000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 88.07 Bn | 86.20 Bn | - | 37.04 Bn |
| 2 | Teva Pharmaceutical Industries | 35.75 Bn | 32.01 Bn | 1.97 Bn | 28.20 Bn |
| 3 | Zoetis | 31.84 Bn | 29.90 Bn | 1.62 Bn | 1.11 Bn |
| 4 | Takeda Pharmaceutical | 27.18 Bn | 23.12 Bn | 4.39 Bn | 4.54 Bn |
| 5 | United Therapeutics | 23.09 Bn | 20.93 Bn | 648.10 Mn | 8.83 Bn |
| 6 | RedHill Biopharma | 21.32 Bn | 21.32 Bn | - | -413.76 Mn |
| 7 | Viatris | 19.96 Bn | 18.16 Bn | 1.16 Bn | 18.66 Bn |
| 8 | Neurocrine Biosciences | 17.66 Bn | 16.34 Bn | 800.70 Mn | 589.60 Mn |
| 9 | Elanco Animal Health | 12.44 Bn | 12.02 Bn | 785.00 Mn | -2.13 Bn |
| 10 | Vireo Growth | 10.53 Bn | 10.38 Bn | 59.30 Mn | -319.90 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 8.83 Bn |
| Dec 31, 2025 | 900,000.00 |
| Sep 30, 2025 | 100,000.00 |
| Jun 30, 2025 | 7.85 Bn |
| Mar 31, 2025 | 7.54 Bn |
| Dec 31, 2024 | 7.22 Bn |
| Sep 30, 2024 | 6.92 Bn |
| Jun 30, 2024 | 6.61 Bn |
| Mar 31, 2024 | 6.33 Bn |
| Dec 31, 2023 | -12.80 Mn |
| Sep 30, 2023 | 5.81 Bn |
| Jun 30, 2023 | 5.54 Bn |
| Mar 31, 2023 | -38.80 Mn |
| Dec 31, 2022 | 5.04 Bn |
| Sep 30, 2022 | -84.10 Mn |
| Jun 30, 2022 | 4.67 Bn |
| Mar 31, 2022 | 4.55 Bn |
| Dec 31, 2021 | -23.00 Mn |
| Sep 30, 2021 | -20.10 Mn |
| Jun 30, 2021 | 4.04 Bn |